Eagle Pharmaceuticals Inc (EGRX) USD0.001

Sell:$1.50Buy:$1.50$0.20 (15.38%)

Prices delayed by at least 15 minutes
Sell:$1.50
Buy:$1.50
Change:$0.20 (15.38%)
Prices delayed by at least 15 minutes
Sell:$1.50
Buy:$1.50
Change:$0.20 (15.38%)
Prices delayed by at least 15 minutes

Company Information

About this company

Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The Company also has a research and development facility in Cambridge, Massachusetts. The Company is also focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. The Company has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana.

Key people

Michael Graves
Interim Executive Chairman of the Board, Interim Principal Executive Officer
Christopher Krawtschuk
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Steven B. Ratoff
Director
Luciana Borio
Independent Director
Richard A. Edlin
Independent Director
Robert L. Glenning
Independent Director
Jennifer K. Simpson
Independent Director
Click to see more

Key facts

  • EPIC
    EGRX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US2697961082
  • Market cap
    $16.88m
  • Employees
    134
  • Shares in issue
    17.54m
  • Exchange
    Over The Counter
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.